Teva: The US Market Leader

Generic SupplementsGeneric Supplement 2010
Volume 0

Teva's mission is to play a leading role in the continuing transformation of and affordable access to health care in the United States.

Teva Logo

By any measure, Teva Pharmaceuticals is the leading generic drug company in the United States. Teva introduced 19 generic products in 2009, and had 210 abbreviated new drug applications pending FDA approval as of April 26, 2010. The company markets the broadest product line in the country, with more than 400 generic products in nearly 1400 dosage strengths and packaging sizes covering all major therapeutic categories. Teva now represents 22% of the US generic prescriptions, with 1 of every 6 US prescriptions being filled with a Teva product.

Teva's Recent Generic Product Introductions

Brand Equivalent

Venlafaxine HCl ER Capsules

Effexor XR

Anastrozole Tablets


Gianvi (Drospirenone and Ethinyl Estradiol Tablets)


Valacyclovir HCl Tablets


Tamsulosin HCl Capsules


Losartan Potassium Tablets USP


Losartan Potassium and HCTZ Tablets


Pramipexole Dihydrochloride Tablets


Budesonide Inhalation Suspension

Pulmicort Respules

Lansoprazole Delayed-Release Capsules USP

Prevacid Delayed-Release

A Global Leader

Teva’s parent company, Teva Pharmaceutical Industries Limited, is the leading generic drug company in the world in terms of both total and new prescriptions. The company’s global presence covers North America, Europe, Latin America, Asia, and Israel, with approximately 60% of its sales generated in North America. Teva now has over 35,000 employees, including more than 6000 within the United States, and annual net sales which totaled $13.9 billion in 2009. Teva operates in more than 60 countries, including 38 finished dosage pharmaceutical manufacturing sites, 15 generic research and development centers, and 21 active pharmaceutical ingredient (API)/ raw material sites around the world, with all pharmaceutical production facilities maintaining one uniform quality standard.


Diversified and Vertically Integrated

In addition to its leadership in the generics market, Teva has a significant and growing branded pharmaceutical portfolio, including COPAXONE for multiple sclerosis, AZILECT for Parkinson’s disease, ProAir for respiratory disorders, and a sizeable women’s health portfolio. The company’s wellestablished and balanced portfolio is supported by a vertically integrated API business. This vertical integration ensures that as Teva continues to grow, the company can maintain its high standard of quality and efficiency, and its longstanding commitment to customer satisfaction.

Innovation in Biosimilars

One example of Teva’s innovation is its continued strides in the emerging biosimilars market—a major growth driver in the company’s long-term strategy. Teva entered into a joint venture with Lonza Group Ltd to develop, manufacture, and market affordable, efficacious, and safe generic equivalents of a selected portfolio of biologic pharmaceuticals. The combination of Teva’s global leadership and expertise in clinical development and marketing of generic pharmaceuticals with Lonza’s deep knowledge and experience in biopharmaceutical development, largescale manufacturing and state-ofthe- art manufacturing facilities, generates significant opportunities and benefits for both companies as well as for patients.


Leading the Way to Affordable Healthcare

Teva’s mission is to play a leading role in the continuing transformation of US health care. The company’s Government Affairs team occupies an office on Capitol Hill and works on behalf of American consumers to advance both innovation and patient access to needed therapies. Last year, Teva launched a nationwide campaign, “Year of Affordable Healthcare,” as a call for increased access to affordable health care for American citizens. Teva is the leading provider of affordable generic medicines. Its robust pipeline of future products is a source of continuing value to American consumers. PT

For more information, visit

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.